Clay Siegall holds a significant investment in Immunome. In 2023, he received stock options for 2,137,080 shares, which vest over four years if he remains with the company. This grant highlights his strong belief in Immunome’s future and aligns his...
Clay Siegall holds a significant investment in Immunome. In 2023, he received stock options for 2,137,080 shares, which vest over four years if he remains with the company. This grant highlights his strong belief in Immunome’s future and aligns his interests with the company's performance. Notably, his wealth largely depends on the success of these stock options, as no other reported vested stocks indicate his commitment. His previous experience at Seagen reflected this kind of alignment; the values of his holdings soared during pivotal phases of growth there. Given his extensive background in biotech, he likely understands how to navigate the complexities of such investments, making him a key figure in Immunome’s potential success.